A total of 23 biopharmaceutical producers have committed capital to the vehicle, which will provide funding for the creation of new antibiotics.
Switzerland-based investment fund Antimicrobial Resistance (AMR) Action Fund has launched with almost $1bn in capital from biopharmaceutical companies to invest in developers of new antibiotics.
AMR Action Fund is intended to operate as a partnership between 23 biopharmaceutical companies with the aim of bringing two to four new antibiotics to market by 2030. It is expected to formally commence operations in the fourth quarter of this year.
Pfizer, Merck & Co and Johnson & Johnson have each pledged $100m in…
